In last trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 7.66 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $3.82 trading at -$0.08 or -2.05% at ring of the bell on the day assigns it a market valuation of $1.25B. That closing price of IOVA’s stock is at a discount of -316.23% from its 52-week high price of $15.90 and is indicating a premium of 6.28% from its 52-week low price of $3.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 15.63 million shares which gives us an average trading volume of 9.38 million if we extend that period to 3-months.
For Iovance Biotherapeutics Inc (IOVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.24 in the current quarter.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Upright in the red during last session for losing -2.05%, in the last five days IOVA remained trading in the red while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $3.82 price level, adding 4.74% to its value on the day. Iovance Biotherapeutics Inc’s shares saw a change of -48.38% in year-to-date performance and have moved -5.68% in past 5-day. Iovance Biotherapeutics Inc (NASDAQ:IOVA) showed a performance of -28.20% in past 30-days. Number of shares sold short was 59.59 million shares which calculate 6.16 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 11.5 to the stock, which implies a rise of 66.78% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 17. It follows that stock’s current price would drop -57.07% in reaching the projected high whereas dropping to the targeted low would mean a loss of -57.07% for stock’s current value.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
This year revenue growth is estimated to rise 173.66% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 83.36M for the same. And 12 analysts are in estimates of company making revenue of 102.38M in the next quarter. Company posted 715k and 31.11M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.17% during past 5 years.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.62% of company’s total shares while institution are holding 83.97 percent of that, with stock having share float percentage of 84.50%. Investors also watch the number of corporate investors in a company very closely, which is 83.97% institutions for Iovance Biotherapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IOVA for having 25.95 million shares of worth $208.12 million. And as of 2024-06-30, it was holding 9.7478 of the company’s outstanding shares.
The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 25.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1052 of outstanding shares, having a total worth of $207.98 million.
